chromium has been researched along with cardiovascular agents in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bian, J; Song, S; Xiang, Y | 1 |
| Liu, T; Ye, ZX; Zhang, QD; Zhang, QF | 1 |
| Büttner, HJ; Gick, M; Leibundgut, G; Löffelhardt, N; Neumann, FJ; Toma, A; Valina, C | 1 |
| Kim, CS; Lee, CW; Lee, S | 1 |
| Allocco, DJ; Cannon, LA; Dawkins, KD; Dens, J; Dubois, CL; Feldman, RL; Lee, TC; Meredith, IT; Mooney, MR; Pompili, VJ; Rabinowitz, AC; Saito, S; Stone, GW; Teirstein, PS | 1 |
| Abbott, JD; Srour, JF | 1 |
| Allocco, DJ; Dawkins, KD; Fang, Q; Gao, R; Han, Y; Hou, Y; Li, H; Wang, H; Xu, B; Yang, Y; Yu, B; Zhang, J | 1 |
| Ando, K; Domei, T; Enomoto, S; Hiromasa, T; Hyodo, M; Iwabuchi, M; Kuramitsu, S; Mazaki, T; Shinozaki, T; Shirai, S; Soga, Y; Yamaji, K | 1 |
| Arana, C; Dager, A; Delgado, JA; Gasior, P; Généreux, P; Granada, JF; Hernandez, H; Higuera, S; Maehara, A; Moncada, M; Vesga, B | 1 |
| Asano, T; de Winter, RJ; Dijkstra, J; Jonker, H; Katagiri, Y; Kimura, T; Kozuma, K; Miyazaki, Y; Onuma, Y; Popma, JJ; Serruys, PW; Sotomi, Y; Stone, GW; Tanabe, K; Tenekecioglu, E; Wykrzykowska, JJ | 1 |
| Fusazaki, T; Hayashi, T; Hibi, K; Ishihara, S; Ito, Y; Kataoka, T; Kikuchi, T; Kuriyama, N; Morino, Y; Morita, T; Otake, H; Otsuka, Y; Shinke, T; Suzuki, T; Tanabe, K; Tanaka, H; Terashita, D | 1 |
| Allocco, DJ; Christen, T; Crowley, J; Ferrario, M; Jung, W; Legrand, V; MacCarthy, P; Meredith, IT; Moreno, R; Redwood, S; Richardt, G; Schwimmbeck, P; Ungi, I; Werner, N; Zaman, A | 1 |
| Benito Gonzalez, T; de la Torre Hernandez, JM; Escaned, J; Garcia Del Blanco, B; Gomez Menchero, A; Gonzalo, N; Hernandez, F; Linares, JA; Moreno, R; Rivera, R; Subinas, A; Veiga Fernandez, G | 1 |
| Cannon, LA; Dawkins, KD; Grady, TP; Hill, R; Kimmelstiel, CD; Myers, PR; Underwood, P; White, A | 1 |
| Allocco, D; Aquino, M; Batchelor, W; Claessen, BE; Davis, S; Gigliotti, OS; Giugliano, G; Guedeney, P; Haghighat, A; Horwitz, PA; Kandzari, DE; Lopez, M; Mehran, R; Meredith, IT; Othman, I; Singh, S; Sorrentino, S; Tamis, L; Underwood, P; Wang, JC | 1 |
| Fujii, K; Fujimoto, Y; Himi, T; Ishikawa, K; Kadohira, T; Kitahara, H; Kobayashi, Y; Oka, N; Sano, K; Takahara, M | 1 |
2 trial(s) available for chromium and cardiovascular agents
| Article | Year |
|---|---|
Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions.
Topics: Aged; Cardiovascular Agents; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Europe; Everolimus; Female; Humans; Japan; Male; Middle Aged; New Zealand; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Design; Sirolimus; Time Factors; Treatment Outcome; United States | 2015 |
PLATINUM China: a prospective, randomized investigation of the platinum chromium everolimus-eluting stent in de novo coronary artery lesions.
Topics: Adult; Aged; Cardiovascular Agents; China; Chromium; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platinum; Prospective Studies; Prosthesis Design; Single-Blind Method; Time Factors; Treatment Outcome | 2015 |
14 other study(ies) available for chromium and cardiovascular agents
| Article | Year |
|---|---|
[Protective effects of chrominum on myocardial damage in rats].
Topics: Animals; Cardiomyopathies; Cardiovascular Agents; Chromium; Doxorubicin; Male; Myocardium; Rats; Rats, Wistar; Selenium | 1996 |
[Study of cardiovascular and cerebrovascular disease in Chinese traditional medicines on Pb, Cr, Cd by AAS].
Topics: Cadmium; Cardiovascular Agents; Chromium; Drugs, Chinese Herbal; Humans; Lead; Neuroprotective Agents; Spectrophotometry, Atomic | 2001 |
Longitudinal compression of the platinum-chromium everolimus-eluting stent during coronary implantation: predisposing mechanical properties, incidence, and predictors in a large patient cohort.
Topics: Aged; Cardiovascular Agents; Chi-Square Distribution; Chromium; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Equipment Failure Analysis; Everolimus; Female; Humans; Logistic Models; Male; Materials Testing; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Prosthesis Failure; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Stress, Mechanical; Tomography, Optical Coherence; Treatment Outcome | 2013 |
FEA study on the stress distributions in the polymer coatings of cardiovascular drug-eluting stent medical devices.
Topics: Arteries; Cardiovascular Agents; Chromium; Drug-Eluting Stents; Finite Element Analysis; Lactic Acid; Materials Testing; Models, Theoretical; Plaque, Atherosclerotic; Platinum; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Steel; Stress, Mechanical | 2014 |
Small vessels and long lesions: changing label indications for drug eluting stents.
Topics: Cardiovascular Agents; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Percutaneous Coronary Intervention; Platinum; Sirolimus | 2015 |
Incidence and Clinical Impact of Stent Fracture After PROMUS Element Platinum Chromium Everolimus-Eluting Stent Implantation.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Chromium; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Incidence; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Prosthesis Failure; Risk Factors; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Cardiovascular Agents; Chromium; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Humans; Lactic Acid; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platinum; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Predictive Value of Tests; Prosthesis Design; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Wound Healing | 2017 |
Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus-eluting bioresorbable polylactide scaffold in comparison with the cobalt-chromium metallic stent?
Topics: Absorbable Implants; Cardiovascular Agents; Chromium; Cobalt; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Sirolimus | 2017 |
Early vascular responses to everolimus-eluting cobalt-chromium stent in the culprit lesions of st-elevation myocardial infarction: results from a multicenter prospective optical coherence tomography study (MECHANISM-AMI 2-week follow-up study).
Topics: Aged; Cardiovascular Agents; Chromium; Cobalt; Coronary Angiography; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; ST Elevation Myocardial Infarction; Tomography, Optical Coherence; Treatment Outcome | 2019 |
Clinical outcomes in unselected patients treated with the PROMUS Element platinum-chromium, everolimus-eluting stent: Final five-year results from the PE PROVE Study.
Topics: Cardiovascular Agents; Chromium; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Europe; Everolimus; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Prospective Studies; Prosthesis Design; Registries; Risk Factors; Time Factors; Treatment Outcome | 2019 |
The Pt-Cr everolimus-eluting stent with bioabsorbable polymer in the treatment of patients with acute coronary syndromes. Results from the SYNERGY ACS registry.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Agents; Chromium; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Recurrence; Registries; Retrospective Studies; Risk Factors; Spain; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2019 |
Clinical outcomes following implantation of the ION™ paclitaxel-eluting platinum chromium coronary stent in routine clinical practice: Results of the ION U.S. post-approval study.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chromium; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Paclitaxel; Platinum; Product Surveillance, Postmarketing; Prospective Studies; Prosthesis Design; Registries; Time Factors; Treatment Outcome; United States | 2019 |
Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies.
Topics: Aged; Cardiovascular Agents; Chromium; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Everolimus; Female; Health Status Disparities; Humans; Male; Middle Aged; Minority Health; Myocardial Infarction; Observational Studies as Topic; Percutaneous Coronary Intervention; Platinum; Prosthesis Design; Race Factors; Registries; Retrospective Studies; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; United States | 2019 |
Assessment of strut coverage of everolimus-eluting platinum chromium stent 2 weeks after implantation by optical coherence tomography.
Topics: Absorbable Implants; Aged; Cardiovascular Agents; Chromium; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Humans; Japan; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Platinum; Polyesters; Prospective Studies; Prosthesis Design; Tomography, Optical Coherence | 2019 |